- The Cooper Companies reported Q1 2025 consolidated revenue of $964.7 million, up 4% year over year and 5% on an organic basis, with gross margin of 68.4% and non-GAAP EPS of $0.92, up 7.4% on a reported basis and 14.2% excluding FX. Net income totaled $104.3 million. Free cash flow was $101.2 million, while net debt decreased to approximately $2.44 billion. The quarter benefited from mix and efficiency gains, even as currency translated into a modest headwind.
- CooperVision delivered 4% reported revenue growth (6% organic) led by toric and multifocal variants and robust MyDay cadence, with capacity expansion running ahead of plan. CooperSurgical grew 3% reported (2% organic) as fertility and capital equipment activity remained solid, underscoring a diversified, high-growth model across eye health and women’s health tech.
- Management reaffirmed full-year guidance: consolidated revenues of $4.08–$4.158 billion, up ~6–8% organically; non-GAAP EPS guidance of $3.94–$4.02 (up 7–9% on a reported basis, 11–13% ex FX); and free cash flow of $350–$400 million. The company highlighted capacity expansion, product launches (notably MyDay and MySite), and a continued push into private label as key growth catalysts. FX headwinds were modest ($0.06 per share negative) but could be offset if FX rates hold.
- The outlook remains constructive with ongoing growth in daily dailies, higher penetration of torics/multifocals, accelerated myopia management, and early-stage plans for MyDay/MySite outside the US. Risks include China softness within CVI, potential PARAGARD competition dynamics, and channel inventory variability. Overall, the stock appears positioned to benefit from operating leverage, ongoing capital deployment, and the long-run expansion of the myopia control market and fertility/consumables endpoints.